mesna Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1711 3375-50-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • mesna
  • mercaptoethanesulfonic acid
  • reduced coenzyme M
A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE.
  • Molecular weight: 142.19
  • Formula: C2H6O3S2
  • CLOGP: -1.55
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 54.37
  • ALOGS: -1.05
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1.20 g Inhal.solution

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 28.13 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 62 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.65 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 20.50 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.36 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 30, 1988 FDA BAXTER HLTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Encephalopathy 395.73 24.04 161 7198 33428 46645275
Febrile neutropenia 362.91 24.04 210 7149 94417 46584286
Mucosal inflammation 217.14 24.04 111 7248 38865 46639838
Pancytopenia 133.45 24.04 109 7250 84949 46593754
Neutropenia 131.70 24.04 136 7223 143068 46535635
Cystitis haemorrhagic 106.30 24.04 34 7325 3513 46675190
Pyrexia 101.84 24.04 190 7169 348612 46330091
Febrile bone marrow aplasia 80.95 24.04 33 7326 6829 46671874
Neurotoxicity 78.97 24.04 40 7319 13677 46665026
Toxic encephalopathy 76.05 24.04 29 7330 5033 46673670
Cytomegalovirus infection 71.13 24.04 41 7318 18103 46660600
Haematotoxicity 67.22 24.04 29 7330 6904 46671799
Product use in unapproved indication 60.83 24.04 73 7286 90200 46588503
Thrombocytopenia 55.54 24.04 83 7276 126498 46552205
Leukopenia 52.26 24.04 59 7300 68284 46610419
Drug ineffective 47.48 24.04 24 7335 677814 46000889
Idiopathic pneumonia syndrome 41.46 24.04 10 7349 362 46678341
Off label use 40.97 24.04 142 7217 379699 46299004
Venoocclusive liver disease 38.66 24.04 17 7342 4234 46674469
Vena cava thrombosis 34.59 24.04 13 7346 2166 46676537
Bone marrow failure 34.27 24.04 32 7327 29637 46649066
BK polyomavirus test positive 34.19 24.04 6 7353 41 46678662
Hypokalaemia 33.37 24.04 54 7305 87970 46590733
Cytokine release syndrome 32.49 24.04 17 7342 6206 46672497
Sepsis 32.08 24.04 68 7291 135946 46542757
Cardiotoxicity 31.26 24.04 17 7342 6705 46671998
Mitral valve disease 30.82 24.04 12 7347 2200 46676503
Anaemia 30.49 24.04 99 7260 255680 46423023
Pneumothorax 29.96 24.04 22 7337 14607 46664096
Chronic hepatitis B 29.16 24.04 7 7352 248 46678455
Periorbital cellulitis 29.04 24.04 8 7351 492 46678211
Arthralgia 28.43 24.04 11 7348 364592 46314111
Blood phosphorus decreased 27.36 24.04 13 7346 3867 46674836
Polyneuropathy 27.26 24.04 19 7340 11625 46667078
Multiple organ dysfunction syndrome 25.68 24.04 36 7323 51674 46627029
Hepatitis E 25.68 24.04 9 7350 1230 46677473
Candida sepsis 24.99 24.04 9 7350 1330 46677373
Hyperuricaemia 24.95 24.04 13 7346 4704 46673999
Posterior reversible encephalopathy syndrome 24.93 24.04 20 7339 15121 46663582

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 416.05 21.10 291 7768 106402 29838017
Encephalopathy 264.88 21.10 142 7917 32063 29912356
Cystitis haemorrhagic 138.06 21.10 51 8008 4736 29939683
Venoocclusive liver disease 115.38 21.10 49 8010 6564 29937855
Pyrexia 91.47 21.10 226 7833 294263 29650156
Pancytopenia 84.49 21.10 109 7950 84943 29859476
Neutropenia 84.07 21.10 135 7924 128405 29816014
Febrile bone marrow aplasia 81.60 21.10 41 8018 8056 29936363
Mucosal inflammation 73.81 21.10 63 7996 30431 29913988
Cytokine release syndrome 65.62 21.10 38 8021 9895 29934524
Haematotoxicity 61.45 21.10 31 8028 6139 29938280
Aplasia 60.88 21.10 27 8032 4010 29940409
Leukopenia 60.49 21.10 75 7984 56084 29888335
Thrombocytopenia 60.10 21.10 121 7938 136923 29807496
Fanconi syndrome 58.96 21.10 21 8038 1754 29942665
Venoocclusive disease 58.15 21.10 23 8036 2567 29941852
Neutrophil count decreased 46.18 21.10 57 8002 42397 29902022
Acute graft versus host disease 45.68 21.10 25 8034 5839 29938580
Foetal growth restriction 41.62 21.10 20 8039 3565 29940854
Neurotoxicity 39.80 21.10 31 8028 13151 29931268
Angiodysplasia 38.17 21.10 11 8048 463 29943956
Polyneuropathy 33.96 21.10 27 8032 11796 29932623
Fusarium infection 33.12 21.10 12 8047 1052 29943367
Fall 32.65 21.10 5 8054 181867 29762552
Stomatitis 31.16 21.10 44 8015 37235 29907184
Bone marrow failure 30.79 21.10 39 8020 29746 29914673
Myelosuppression 30.69 21.10 21 8038 7301 29937118
Drug ineffective 30.66 21.10 28 8031 340359 29604060
Chronic graft versus host disease 30.54 21.10 17 8042 4102 29940317
Acute graft versus host disease in skin 29.08 21.10 17 8042 4499 29939920
Septic shock 27.59 21.10 56 8003 63551 29880868
Death 27.03 21.10 34 8025 357249 29587170
Staphylococcal bacteraemia 25.08 21.10 18 8041 6750 29937669
Non-Hodgkin's lymphoma unspecified histology aggressive 24.71 21.10 5 8054 44 29944375
Drug therapeutic incompatibility 24.59 21.10 6 8053 131 29944288
Cytomegalovirus hepatitis 24.07 21.10 7 8052 304 29944115
Off label use 24.02 21.10 131 7928 249159 29695260
Anaemia 24.01 21.10 115 7944 207877 29736542
Myocardial infarction 23.59 21.10 3 8056 125622 29818797
Osmotic demyelination syndrome 22.34 21.10 8 8051 678 29943741
Pulpitis dental 22.23 21.10 7 8052 399 29944020
Low birth weight baby 22.15 21.10 16 8043 6060 29938359
Chloroma 21.59 21.10 7 8052 439 29943980
Agranulocytosis 21.52 21.10 28 8031 21914 29922505
Pulmonary toxicity 21.45 21.10 14 8045 4502 29939917
Toxic encephalopathy 21.18 21.10 14 8045 4595 29939824

Pharmacologic Action:

SourceCodeDescription
ATC R05CB05 RESPIRATORY SYSTEM
COUGH AND COLD PREPARATIONS
EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS
Mucolytics
ATC V03AF01 VARIOUS
ALL OTHER THERAPEUTIC PRODUCTS
ALL OTHER THERAPEUTIC PRODUCTS
Detoxifying agents for antineoplastic treatment
MeSH PA D020011 Protective Agents
CHEBI has role CHEBI:23354 coenzymes

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Testicular Germ Cell Tumor indication
Prevention of Chemotherapy-Induced Hemorrhagic Cystitis indication
Ewing's sarcoma off-label use 76909002 DOID:3369
Burkitt's lymphoma off-label use 118617000
Non-small cell lung cancer off-label use 254637007 DOID:3908
Malignant tumor of head and/or neck off-label use 255056009
Osteosarcoma of bone off-label use 307576001 DOID:3376
Soft or Connective Tissue Sarcoma off-label use
Renal tubular acidosis contraindication 1776003 DOID:14219
Hyperbilirubinemia contraindication 14783006 DOID:2741
Dehydration contraindication 34095006
Fanconi syndrome contraindication 40488004 DOID:1062
Hypokalemia contraindication 43339004
Leukopenia contraindication 84828003 DOID:615
Kidney disease contraindication 90708001 DOID:557
Kidney excision contraindication 108022006
Liver function tests abnormal contraindication 166603001
Disease of liver contraindication 235856003 DOID:409
Impaired wound healing contraindication 271618001
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Bone marrow depression contraindication 307762000
Coma contraindication 371632003
Impaired cognition contraindication 386806002
Breastfeeding (mother) contraindication 413712001
Cancer Chemotherapy Induced Hemorrhagic Cystitis contraindication
Polyneuropathies contraindication
Severe Bone Marrow Depression contraindication
Bone Metastases contraindication
CNS Toxicity contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 0.61 acidic
pKa2 9.77 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4019477 VUID
N0000147597 NUI
D01459 KEGG_DRUG
19767-45-4 SECONDARY_CAS_RN
4019477 VANDF
C0000294 UMLSCUI
CHEBI:17905 CHEBI
COM PDB_CHEM_ID
CHEMBL975 ChEMBL_ID
CHEMBL1098319 ChEMBL_ID
D015080 MESH_DESCRIPTOR_UI
DB09110 DRUGBANK_ID
2813 INN_ID
NR7O1405Q9 UNII
23662354 PUBCHEM_CID
1546354 RXNORM
41498 MMSL
5057 MMSL
d01411 MMSL
002678 NDDF
108821000 SNOMEDCT_US
386922000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
MESNEX HUMAN PRESCRIPTION DRUG LABEL 1 0338-1305 INJECTION, SOLUTION 100 mg INTRAVENOUS NDA 27 sections
MESNULL HUMAN PRESCRIPTION DRUG LABEL 1 10019-951 INJECTION, SOLUTION 100 mg INTRAVENOUS NDA 26 sections
MESNULL HUMAN PRESCRIPTION DRUG LABEL 1 10019-953 INJECTION, SOLUTION 100 mg INTRAVENOUS NDA 26 sections
Mesna HUMAN PRESCRIPTION DRUG LABEL 1 25021-201 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 26 sections
Mesna HUMAN PRESCRIPTION DRUG LABEL 1 25021-201 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 26 sections
Mesna Human Prescription Drug Label 1 63323-733 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 27 sections
MESNEX HUMAN PRESCRIPTION DRUG LABEL 1 67108-3565 TABLET, FILM COATED 400 mg ORAL NDA 26 sections
Mesna Human Prescription Drug Label 1 68083-161 SOLUTION 100 mg INTRAVENOUS ANDA 26 sections
Mesna HUMAN PRESCRIPTION DRUG LABEL 1 70860-209 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 27 sections